Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Rises By 38.0%

Tharimmune, Inc. (NASDAQ:THAR) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 36,300 shares, an increase of 38.0% from the February 13th total of 26,300 shares. Approximately 1.9% of the company’s shares are short sold. Based on an average trading volume of 98,300 shares, the days-to-cover ratio is currently 0.4 days.

Tharimmune Stock Performance

Shares of NASDAQ:THAR traded up $0.02 during trading on Tuesday, reaching $1.43. 426 shares of the company were exchanged, compared to its average volume of 348,716. The business’s fifty day simple moving average is $1.83 and its 200-day simple moving average is $2.18. Tharimmune has a 12-month low of $1.28 and a 12-month high of $7.46.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC purchased a new stake in shares of Tharimmune, Inc. (NASDAQ:THAR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned 2.06% of Tharimmune at the end of the most recent quarter. Institutional investors and hedge funds own 1.16% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on THAR shares. RODMAN&RENSHAW raised shares of Tharimmune to a “strong-buy” rating in a research note on Friday, December 6th. Rodman & Renshaw assumed coverage on Tharimmune in a report on Friday, December 6th. They issued a “buy” rating and a $17.00 price target on the stock.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).